Biohaven buys PRV from GW Pharmaceuticals for USD 105 million
GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review
voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug
Administration programme to accelerate speedy recovery of rare disease. GW received the voucher
when FDA approved its cannabinoid medicine Epidiolex for treating seizures.
BioMed Realty acquires Emeryville Center for Innovation
BioMed Realty-a blackstone portfolio company has acquired Emeryville Center for Innovation for USD
135 million. This campus acquisition of around 250,000 square foot, six-story life science office building
will help BioMed to dominate the market of Life Sciences in San Francisco.
Merck, Iktos to explore AI for drug discovery
Merck, a leading science and technology company has decided to use its generative modelling artificial
intelligence (AI) technology to facilitate the rapid and cost-effective discovery and design of promising
new compounds in collaboration with Iktos’ AI technology.
Merck, and GenScript for Cell and Gene Therapy in China
Merck among the only few to industrialize the process of making viral vectors has now announced its
decision to commercialize the Cell and Gene therapy in collaboration with GenScript- a China biotech
company. Merck will extend its support in processing products, services and staff training to GenScript
to accelerate the manufacturing of plasmids and viral vectors.